… Apixaban, an oral direct factor Xa inhibitor, is currently in late … (VTE) prophylaxis, apixaban
has shown decreased rates of … Secondary treatment of VTE with apixaban is currently in …

… new oral anticoagulant agents have been developed that may offer an alternative to warfarin.
Emerging data suggest that Factor Xa … Direct Factor Xa inhibitors bind to Factor Xa with 1:1 …

… new class of oral anticoagulants in patients with atrial fibrillation. In patients with acute coronary
syndrome, apixaban … course of thromboprophylaxis with apixaban was not superior to a …

… Efficacy profile of apixaban Apixaban is an oral selective direct factor Xa inhibitor, approved
by European commission, in May 2011 for the prevention of thromboembolic complications …

… This review focuses on the pre-clinical discovery of apixaban, a promising new oral … of
the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor …

… , new oral agents targeted to inhibit thrombin or factor Xa have … Apixaban is a highly
selective, potent and orally bioavailable inhibitor of both free and prothrombinase-bound factor Xa. …

… Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a
… This review is timely since new results from Phase III trials of apixaban have recently been …

… Apixaban is an oral factor Xa inhibitor … the new direct Xa inhibitors. In this study, mPT was
found to have greater sensitivity to apixaban and exhibited a linear relationship with apixaban …

… in patients with recent acute coronary syndromes, which, depending on their results, may
establish oral anticoagulation as a new standard approach for preventing recurrent ischemic …

… , 0.05 ± 0.01, 0.05 ± 0.01, 0.27 ± 0.08 and > 3 mg kg −1 h −1 iv for the indirect FXa inhibitor …
1 po for the oral anticoagulant warfarin, respectively. Conclusions: In summary, apixaban was …